- 现金
- 271 元
- 精华
- 0
- 帖子
- 81
- 注册时间
- 2018-7-13
- 最后登录
- 2023-6-19
|
回复 newchinabok 的帖子
Arrowhead Begins Triple Combination Cohort in Chronic HBV Patients and Earns $25 Million
Milestone Payment from Janssen
April 24, 2019
PASADENA, Calif.--(BUSINESS WIRE)--Apr. 24, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has begun
dosing in a new triple combination cohort (cohort 12) that includes JNJ-3989 (formerly ARO-HBV) and additional undisclosed agents selected by
Janssen Pharmaceuticals, Inc. in its ongoing Phase 1/2 study (AROHBV1001) in patients with chronic hepatitis B virus (HBV). In connection with the
start of this new cohort, Arrowhead has earned a $25 million milestone payment from Janssen Pharmaceuticals, Inc., part of the Janssen
Pharmaceutical Companies of Johnson & Johnson.
Christopher Anzalone, Ph.D., president and chief executive officer at Arrowhead, said: “Both Arrowhead and Janssen share the aim to advance
transformational medicines that achieve higher rates of functional cure with a finite treatment duration for patients with chronic hepatitis B viral
infection. Beginning this new triple combination cohort in our ongoing AROHBV1001 study has the potential to generate valuable data rapidly.”
AROHBV1001 (NCT03365947) is a Phase 1/2 clinical study evaluating the safety, tolerability, and pharmacokinetic effects of single-ascending doses
(SAD) of ARO-HBV in healthy adult volunteers, as well as the safety, tolerability, and pharmacodynamic effects of multiple-ascending doses (MAD) of
ARO-HBV in patients with chronic HBV.
Arrowhead entered into a license and collaboration agreement with Janssen in October 2018 to develop and commercialize ARO-HBV. Under the
initial terms of the HBV license agreement, Arrowhead was eligible to receive a $50 million milestone payment linked to a Phase 2 study. Arrowhead
and Janssen subsequently amended the HBV license agreement to accelerate the payment of $25 million of the $50 million Phase 2 milestone with
the initiation of cohort 12 of the AROHBV1001 trial. Arrowhead is eligible to receive the remaining $25 million upon the initiation of a Phase 2 study by
Janssen.
Hepatitis B |
|